...
首页> 外文期刊>Breast cancer research and treatment. >The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
【24h】

The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.

机译:在中国汉族高危乳腺癌患者中,BRCA1和BRCA2种系突变的患病率:确定了两个复发突变。

获取原文
获取原文并翻译 | 示例
           

摘要

To have an overview of the role of BRCA1 and BRCA2 genes among Chinese high-risk breast cancer patients, we analyzed 489 such high-risk breast cancer patients from four breast disease clinical centers in China, by using PCR-DHPLC or SSCP-DNA sequencing analysis. Allelotype analysis was done at five short tandem repeat (STR) markers in or adjacent to BRCA1 on the recurrent mutation carriers. For those analyzed both genes, 8.7% of early-onset breast cancer cases and 12.9% of familial breast cancer cases had a BRCA1 or BRCA2 mutation, as compared with the 26.1% of cases with both early-onset breast cancer and affected relatives. For those reporting malignancy family history other than breast/ovarian cancer, the prevalence of BRCA1/2 mutation is about 20.5%, and it was significantly higher than the patients only with family history of breast/ovarian cancer (P = 0.02). The family history of ovarian cancer (26.7% vs. 11.9%) and stomach cancer (23.8% vs. 11.8%) doubled the incidence of BRCA1/2, but the difference did not reach the statistical significance. Two recurrent mutations in BRCA1, 1100delAT and 5589del8, were identified. The recurrent mutations account for 34.8% BRCA1 mutations in our series. Similar allelotypes were detected in most STR status for those harboring the same mutations. The BRCA1 associated tumors were more likely to exhibit a high tumor grade, negative C-erbB-2eu status and triple negative (ER, PgR and C-erbB-2eu negative) status (P < 0.05). We recommended the BRCA1 and BRCA2 genetic analysis could be done for high-risk breast cancer patient in Chinese population, especially for those with both early-onset breast cancer and affected relatives. There may be some degree of shared ancestry for the two recurrent BRCA1 mutations in Chinese.
机译:为了概述BRCA1和BRCA2基因在中国高危乳腺癌患者中的作用,我们使用PCR-DHPLC或SSCP-DNA测序方法分析了来自中国四个乳腺疾病临床中心的489名此类高危乳腺癌患者分析。在复发突变携带者的BRCA1内或附近的五个短串联重复序列(STR)标记上进行了等位基因型分析。对于这两个基因的分析者,早发性乳腺癌病例的8.7%和家族性乳腺癌病例的12.9%具有BRCA1或BRCA2突变,而早发性乳腺癌和患病亲属的26.1%。对于那些报告乳腺癌而非卵巢癌恶性家族史的人,BRCA1 / 2突变的患病率约为20.5%,并且显着高于仅具有乳腺癌/卵巢癌家族史的患者(P = 0.02)。卵巢癌(26.7%对11.9%)和胃癌(23.8%对11.8%)的家族史使BRCA1 / 2的发生率增加了一倍,但差异没有统计学意义。鉴定出BRCA1中的两个重复突变1100delAT和5589del8。复发突变占我们系列中BRCA1突变的34.8%。对于大多数具有相同突变的个体,在大多数STR状态中都检测到了类似的等位基因型。与BRCA1相关的肿瘤更有可能表现出较高的肿瘤等级,阴性的C-erbB-2 / neu状态和三阴性(ER,PgR和C-erbB-2 / neu阴性)状态(P <0.05)。我们建议对中国人群中的高危乳腺癌患者,尤其是既有早发性乳腺癌又有相关亲属的人群,应进行BRCA1和BRCA2遗传分析。汉语中两个反复出现的BRCA1突变可能有一定程度的共同祖先。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号